> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Review for Genentech Bladder Cancer sBLA
- URL: https://www.fdaweb.com/priority-review-for-genentech-bladder-cancer-sbla/
- Published: 2017-01-09T12:00:00.000Z
- Updated: 2026-09-14T21:58:48.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5137661

FDA has accepted for priority review a Genentech supplemental BLA for Tecentriq (atezolizumab) for treating people with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin chemotherapy, and are either previously untreated (first-line) or have disease progression at least 12 months after receiving chemotherapy before surgery (neoadjuvant) or after surgery (adjuvant). Urothelial carcinoma makes up about 90% of all bladder cancers and can also be found in the renal pelvis, ureter and urethra.

The submission is based on results from the Phase 2 IMvigor210 study. FDA has set a 4/30 user fee review target date. Last May, the therapy became the [first treatment approved](https://www.fdaweb.com/fda-approves-genentechs-tecentriq-for-lung-cancer/) by the agency in more than 30 years for people with previously treated advanced bladder cancer, the company says.